Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
DENTSPLY SIRONA $750 million notes offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering by…
Gamida Cell $60 million follow-on offering
Davis Polk advised the representatives of the underwriters in connection with the $60 million SEC-registered follow-on…
Turning Point Therapeutics $325 million stock offering
Davis Polk advised the joint book-running managers in connection with a $325 million SEC-registered common stock…
ADC Therapeutics $267 million IPO
Davis Polk advised ADC Therapeutics SA on its SEC-registered initial public offering of 14,082,475 common shares, which…
Insulet $500 million stock offering
Davis Polk advised the underwriters in connection with the public offering of 2,369,668 shares of common stock of…
Cantel Medical $140 million convertible senior notes offering
Davis Polk the initial purchasers in connection with a Rule 144A offering by Cantel Medical Corp. of $140 million…
Alector $150 million at-the-market offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Alector, Inc. of…
AtriCure $201.2 million follow-on offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a SEC…
DexCom $1.05 billion convertible notes offering
Davis Polk advised the representatives of several initial purchasers in connection with a Rule 144A offering by DexCom,…
Affimed $50 million at-the-market offering program
Davis Polk advised the sales agent in connection with the establishment of an SEC-registered at-the-market offering…